First patent application to use Neuregulin-1 to treat chronic heart failure（PCT/AU99/01137）
First innovative medicine in development targeting NRG-1 - ErbB2/4 to treat heart failure with cardiomyocytes repair.
First innovative medicine in development targeting cMLCK to treat severe heart failure. （PCT/CN2007/002531）
First patent application to treat chronic diastolic heart failure with Neuregulin-1 (CN201410550212.7; PCT/CN2015/091459)
First patent application to treat diabetes induced heart failure with Neuregulin-1（PCT/CN2012/001353）
First patent application to treat myocardial infarction with Neuregulin-1（CN2010101112974.0; PCT/CN2011/070178）
First patent application to treat Viral Myocarditis with Neuregulin-1（PCT/CN02/00349）
First patent application to treat Ventricular Arrhythmia with Neuregulin-1（CN201410529437.4;PCT/CN2015/088972）
First innovative medicine in development reducing 60-80% all-cause mortality of target patients（NT-proBNP<1600 fmol/mL）with the direction of precision medicine
One of the earliest international “First-in-Class”innovative medicines under development in China
One of the earliest innovative medicines in China that have completed phase II clinical trial in U.S.
Become World Advanced Biotechnology Company as the leader of Chinese innovative medicines producers
The research of Zensun innovative medicines started from receptor tyrosine kinases (RTKs), especially the ErbB receptor family. For past twenty years, Zensun has focused on the research of ErbB receptor family, RTKs and their downstream-activated signaling pathways and has tried to find out the relationship between ErbB and heart diseases including the effects of ErbB4 signaling pathway on cardiomyocytes for the promotion of cell growth and survival, the maintenance of sarcomeric structural organization, and the enhancement of systolic and diastolic function. In ErbB2/ErbB4 downstream gene signaling pathway study, cardiac-specific myosin light kinase (cMLCK) shows effectiveness of heart failure treatment. Zensun also has discovered that ErbB2-ErbB3 heterodimer is a signal for formation and growth of tumorigenesis and tumor. The therapeutic cancer vaccine rhErbB3-f has been developed, which brings a new perspective to tumor immunotherapy.
Curiosity about science and deep understanding of mechanism is the starting point and driving force of Zensun innovative medicines. Zensun will keep focus on scientific and technological innovation and will finally become world advanced biotechnology company as the leader of Chinese innovative medicines producers.